These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38002270)

  • 41. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
    Dai Y; Rahmani M; Dent P; Grant S
    Mol Cell Biol; 2005 Jul; 25(13):5429-44. PubMed ID: 15964800
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
    Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
    Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
    Oh ET; Park MT; Choi BH; Ro S; Choi EK; Jeong SY; Park HJ
    Invest New Drugs; 2012 Apr; 30(2):435-42. PubMed ID: 20978925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups.
    Li Y; Wang F; Chen X; Wang J; Zhao Y; Li Y; He B
    Curr Top Med Chem; 2019; 19(3):223-241. PubMed ID: 30674261
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma.
    Zhang CZ; Chen GG; Merchant JL; Lai PB
    Cell Cycle; 2012 Jan; 11(2):322-34. PubMed ID: 22214764
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HDAC inhibition promotes neuronal outgrowth and counteracts growth cone collapse through CBP/p300 and P/CAF-dependent p53 acetylation.
    Gaub P; Tedeschi A; Puttagunta R; Nguyen T; Schmandke A; Di Giovanni S
    Cell Death Differ; 2010 Sep; 17(9):1392-408. PubMed ID: 20094059
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation.
    Beliakova-Bethell N; Mukim A; White CH; Deshmukh S; Abewe H; Richman DD; Spina CA
    J Biol Chem; 2019 Apr; 294(14):5576-5589. PubMed ID: 30745362
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension.
    Chen F; Li X; Aquadro E; Haigh S; Zhou J; Stepp DW; Weintraub NL; Barman SA; Fulton DJR
    Free Radic Biol Med; 2016 Oct; 99():167-178. PubMed ID: 27498117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
    Yue K; Qin M; Huang C; James Chou C; Jiang Y; Li X
    Bioorg Med Chem Lett; 2022 Aug; 70():128797. PubMed ID: 35580726
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design, synthesis, and biological evaluation of histone deacetylase inhibitor with novel salicylamide zinc binding group.
    Kim JH; Ali KH; Oh YJ; Seo YH
    Medicine (Baltimore); 2022 Apr; 101(17):e29049. PubMed ID: 35512065
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heterocyclic Moieties as HDAC Inhibitors: Role in Cancer Therapeutics.
    Tasneem S; Alam MM; Amir M; Akhter M; Parvez S; Verma G; Nainwal LM; Equbal A; Anwer T; Shaquiquzzaman M
    Mini Rev Med Chem; 2022; 22(12):1648-1706. PubMed ID: 34939540
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plakoglobin restores tumor suppressor activity of p53
    Alaee M; Nool K; Pasdar M
    Cancer Sci; 2018 Jun; 109(6):1876-1888. PubMed ID: 29660231
    [TBL] [Abstract][Full Text] [Related]  

  • 53. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
    Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
    J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multifunctional metallochaperone modifications for targeting subsite cavities in mutant p53-Y220C.
    Miller JJ; Kwan K; Blanchet A; Orvain C; Mellitzer G; Smith J; Lento C; Nouchikian L; Omoregbee-Leichnitz S; Sabatou M; Wilson D; Gaiddon C; Storr T
    J Inorg Biochem; 2023 May; 242():112164. PubMed ID: 36871418
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms.
    Uo T; Veenstra TD; Morrison RS
    J Neurosci; 2009 Mar; 29(9):2824-32. PubMed ID: 19261878
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
    Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
    Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity.
    Godoy LD; Lucas JE; Bender AJ; Romanick SS; Ferguson BS
    Mol Nutr Food Res; 2017 Apr; 61(4):. PubMed ID: 27981795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Histone deacetylase inhibitors: Potential in cancer therapy.
    Marks PA; Xu WS
    J Cell Biochem; 2009 Jul; 107(4):600-8. PubMed ID: 19459166
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.
    Fortson WS; Kayarthodi S; Fujimura Y; Xu H; Matthews R; Grizzle WE; Rao VN; Bhat GK; Reddy ES
    Int J Oncol; 2011 Jul; 39(1):111-9. PubMed ID: 21519790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.